NCT06739499

Brief Summary

The BEready project aims to find out how people in the Canton of Bern can be helped to be more prepared for the next pandemic. BEready wants to understand how infections spread among people as well as between people and animals. BEready wants to find out how social and environmental factors can influence the transmission or catching of infectious diseases. BEready wants to better understand how households and their pets in the Canton of Bern were and continue to be affected by the coronavirus disease 2019 (COVID-19).

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,157

participants targeted

Target at P75+ for all trials

Timeline
908mo left

Started Apr 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Apr 2024Dec 2100

Study Start

First participant enrolled

April 29, 2024

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

December 9, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 18, 2024

Completed
76.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2100

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2100

Last Updated

February 5, 2026

Status Verified

February 1, 2026

Enrollment Period

76.7 years

First QC Date

December 9, 2024

Last Update Submit

February 2, 2026

Conditions

Keywords

One HealthPandemic preparednessCommunity engagement

Outcome Measures

Primary Outcomes (13)

  • Response rate among the randomly sampled participants

    Percentage agreeing to take part, divided by the number invited, by age and sex (study level)

    Baseline

  • Attendance of follow up visits (to derive factors associated with research participation)

    Percentage of completed questionnaire (study level)

    At every annual follow-up for up to 100 years

  • Incidence of respiratory virus detection in symptomatic persons

    Test positivity: percentage of nasal swab samples with a positive result for specific respiratory viruses among all viruses detected amongst those reporting disease events cumulatively by the end of one year; incidence rate for any detected virus and for specific viruses: number of nasal swab samples with a positive result per 100 person years of follow-up (individual level, infection-related)

    At the end of a 12 months period

  • Seroprevalence of antibodies to respiratory viruses

    Proportion of serum samples with antibodies to specific respiratory viruses (individual level, infection-related)

    At baseline and annually thereafter for up to 100 years

  • Incidence of co-infection/co-colonisation at the pet/owner interface

    Proportion of serum samples with antibodies to specific parasites (individual level, infection-related)

    Throughout follow-up for up to 100 years

  • Incidence of animal diseases diagnosed through syndromic surveillance

    Based on each case definition, e.g. febrile illness, incidence of syndromic diagnoses by month (individual level, infection-related)

    Throughout follow-up for up to 100 years

  • Prevalence of post-acute viral symptoms

    Individual level, infection-related

    At baseline and annually thereafter for up to 100 years

  • Gender roles

    Gender is a cross-cutting theme. Associations with gender measured by questionnaire will be examined for all endpoints (individual level, personal, social, demographic).

    At all timepoints for up to 100 years

  • Number of daily social contacts

    Numbers of social contacts between humans, according to age group and location (individual level, personal, social, demographic)

    At baseline and annually thereafter for up to 100 years

  • Affective polarisation

    Mean and standard deviation of Likert scale scores (individual level, personal, social, demographic)

    At baseline

  • Knowledge of pandemic preparedness

    Knowledge measured by questionnaire. Summary of the survey data (individual level, personal, social, demographic)

    At baseline

  • Knowledge of vector-borne diseases

    Knowledge measured by questionnaire. Summary of the survey data (individual level, personal, social, demographic)

    At baseline

  • Experienced marginalisation

    Experience measured by questionnaire. Summary of the survey data (individual level, personal, social, demographic)

    At baseline

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

BEready will include a spectrum of the Bernese population living in private households, including adults, children and pets. A private household is defined as a person living alone or group of persons living in the same dwelling. The study population for the BEready cohort will be enrolled from different sources in the source population of the canton of Bern. BEready aims to enrol around 1,500 households in total from: * Households already participating in the BEready pilot study * A random selection of households in Bern using the cantonal residents' register * Volunteer households from the general public

You may qualify if:

  • Informed consent
  • Residence (average of more than 3 days/week) in a private household in the canton of Bern where at least one member aged 18 agreed to take part.
  • For adults, children aged 14 years or older, and parents/legal guardians: internet connection (Wi-Fi, fixed or on a mobile phone) and personal email address.
  • For adults, children aged 11 years or older, and parents/legal guardians: able to understand, speak, read and write German, French and/or English.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Bern

Bern, 3012, Switzerland

Location

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Blood, nasal swabs

MeSH Terms

Conditions

COVID-19InfectionsZoonosesRespiratory Tract Infections

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesAnimal Diseases

Study Officials

  • Nicola Low, Prof. Dr. med.

    University of Bern

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 9, 2024

First Posted

December 18, 2024

Study Start

April 29, 2024

Primary Completion (Estimated)

December 31, 2100

Study Completion (Estimated)

December 31, 2100

Last Updated

February 5, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

Upon request

Locations